Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.

Blood - 15 May 2008

Xing Shu, Wanting Tina Ho, Zhao Wanming, Ma Junfeng, Wang Shaofeng, Xu Xuesong, Li Qingshan, Fu Xueqi, Xu Mingjiang, Zhao Zhizhuang Joe

Abstract excerpt

The JAK2(V617F) mutation was found in most patients with myeloproliferative disorders (MPDs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. We have generated transgenic mice expressing the mutated enzyme in the hematopoietic system driven by a vav gene promote...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythropoietin
Share to Hematopoietic Stem Cells
Share to Hyperplasia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation, Missense

Share to Myeloproliferative Disorders

Share to Thrombopoietin

Share to Transgenes

Source

Open in PubMed Open full text

Identifiers

PMID: 18334677
DOI: 10.1182/blood-2007-05-091579
PMCID: PMC2384138

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18334677-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.PMID 18334677Read ↗

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.Semantic proximity Read ↗

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.Semantic proximity Read ↗

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseSemantic proximity Read ↗

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemiaSemantic proximity Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in miceSemantic proximity Read ↗

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.Semantic proximity Read ↗

Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasmsSemantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Semantic proximity Read ↗

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.Semantic proximity Read ↗

Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.